Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr 10:15:348.
doi: 10.1186/s12889-015-1680-y.

The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy

Céline Schurmans  1 , Irith De Baetselier  2 , Evelyne Kestelyn  3   4 , Vicky Jespers  5 , Thérèse Delvaux  6 , Stephen K Agaba  7 , Harry van Loen  8 , Joris Menten  9 , Janneke van de Wijgert  10 , Tania Crucitti  11 ; RING PLUS study group
Affiliations
Randomized Controlled Trial

The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy

Céline Schurmans et al. BMC Public Health. .

Abstract

Background: Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available.

Methods: We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology.

Discussion: In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets.

Trial registration: Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schedule of the clinical study.
Figure 2
Figure 2
Schedule of assessments.
See this image and copyright information in PMC

References

    1. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56:954–6. doi: 10.1093/jac/dki326. - DOI - PubMed
    1. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 2010;88(Suppl 1):S30–9. doi: 10.1016/j.antiviral.2010.09.003. - DOI - PubMed
    1. Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441–51. - PMC - PubMed
    1. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51:416–23. doi: 10.1097/QAI.0b013e3181acb536. - DOI - PubMed
    1. Murphy DJ, Desjardins D, Dereuddre-Bosquet N, Brochard P, Perrot L, Pruvost A, et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. J Antimicrob Chemother. 2014;69:2477–88. doi: 10.1093/jac/dku160. - DOI - PubMed

Publication types

Associated data